| pubmed-article:20530506 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20530506 | lifeskim:mentions | umls-concept:C1265292 | lld:lifeskim |
| pubmed-article:20530506 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:20530506 | lifeskim:mentions | umls-concept:C0007732 | lld:lifeskim |
| pubmed-article:20530506 | lifeskim:mentions | umls-concept:C0158371 | lld:lifeskim |
| pubmed-article:20530506 | lifeskim:mentions | umls-concept:C1517004 | lld:lifeskim |
| pubmed-article:20530506 | lifeskim:mentions | umls-concept:C2001521 | lld:lifeskim |
| pubmed-article:20530506 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:20530506 | pubmed:dateCreated | 2010-7-16 | lld:pubmed |
| pubmed-article:20530506 | pubmed:abstractText | To evaluate the activity of a new cephalosporin, ceftaroline, in comparison with other antistaphylococcal drugs (linezolid and vancomycin) at projected human therapeutic doses against methicillin-resistant Staphylococcus aureus (MRSA) and glycopeptide-intermediate S. aureus (GISA) strains. | lld:pubmed |
| pubmed-article:20530506 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20530506 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20530506 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20530506 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20530506 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20530506 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20530506 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20530506 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20530506 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20530506 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20530506 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20530506 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:20530506 | pubmed:issn | 1460-2091 | lld:pubmed |
| pubmed-article:20530506 | pubmed:author | pubmed-author:BatardEricE | lld:pubmed |
| pubmed-article:20530506 | pubmed:author | pubmed-author:HamelAntoineA | lld:pubmed |
| pubmed-article:20530506 | pubmed:author | pubmed-author:CaillonJocely... | lld:pubmed |
| pubmed-article:20530506 | pubmed:author | pubmed-author:PotelGillesG | lld:pubmed |
| pubmed-article:20530506 | pubmed:author | pubmed-author:GeYigongY | lld:pubmed |
| pubmed-article:20530506 | pubmed:author | pubmed-author:JacquelineCéd... | lld:pubmed |
| pubmed-article:20530506 | pubmed:author | pubmed-author:Le... | lld:pubmed |
| pubmed-article:20530506 | pubmed:author | pubmed-author:BiekDonaldD | lld:pubmed |
| pubmed-article:20530506 | pubmed:author | pubmed-author:MiègevilleAnn... | lld:pubmed |
| pubmed-article:20530506 | pubmed:author | pubmed-author:AmadorGillesG | lld:pubmed |
| pubmed-article:20530506 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20530506 | pubmed:volume | 65 | lld:pubmed |
| pubmed-article:20530506 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20530506 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20530506 | pubmed:pagination | 1749-52 | lld:pubmed |
| pubmed-article:20530506 | pubmed:meshHeading | pubmed-meshheading:20530506... | lld:pubmed |
| pubmed-article:20530506 | pubmed:meshHeading | pubmed-meshheading:20530506... | lld:pubmed |
| pubmed-article:20530506 | pubmed:meshHeading | pubmed-meshheading:20530506... | lld:pubmed |
| pubmed-article:20530506 | pubmed:meshHeading | pubmed-meshheading:20530506... | lld:pubmed |
| pubmed-article:20530506 | pubmed:meshHeading | pubmed-meshheading:20530506... | lld:pubmed |
| pubmed-article:20530506 | pubmed:meshHeading | pubmed-meshheading:20530506... | lld:pubmed |
| pubmed-article:20530506 | pubmed:meshHeading | pubmed-meshheading:20530506... | lld:pubmed |
| pubmed-article:20530506 | pubmed:meshHeading | pubmed-meshheading:20530506... | lld:pubmed |
| pubmed-article:20530506 | pubmed:meshHeading | pubmed-meshheading:20530506... | lld:pubmed |
| pubmed-article:20530506 | pubmed:meshHeading | pubmed-meshheading:20530506... | lld:pubmed |
| pubmed-article:20530506 | pubmed:meshHeading | pubmed-meshheading:20530506... | lld:pubmed |
| pubmed-article:20530506 | pubmed:meshHeading | pubmed-meshheading:20530506... | lld:pubmed |
| pubmed-article:20530506 | pubmed:meshHeading | pubmed-meshheading:20530506... | lld:pubmed |
| pubmed-article:20530506 | pubmed:meshHeading | pubmed-meshheading:20530506... | lld:pubmed |
| pubmed-article:20530506 | pubmed:meshHeading | pubmed-meshheading:20530506... | lld:pubmed |
| pubmed-article:20530506 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20530506 | pubmed:articleTitle | Efficacy of the new cephalosporin ceftaroline in the treatment of experimental methicillin-resistant Staphylococcus aureus acute osteomyelitis. | lld:pubmed |
| pubmed-article:20530506 | pubmed:affiliation | Université de Nantes, Faculté de Médecine, Thérapeutiques Cliniques et Expérimentales des Infections, EA3826, F-44000 Nantes, France. cedric.jacqueline@univ-nantes.fr | lld:pubmed |
| pubmed-article:20530506 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20530506 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:20530506 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
